• About us
• Contact

Advertisement

Document › Details

Pharmalink AB. (8/24/17). "Press Release: Thomas Eklund New Chairman of Pharmalink". Stockholm.

	Organisation	Pharmalink AB
	Today	Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
	Group	Calliditas Therapeutics (Group)
	Organisation 2	Investor Growth Capital
	Group	Investor AB (Wallenberg) (Group)
	Product	Nefecon®
	Product 2	finance
	Person	Eklund, Thomas (Investor Growth Capital + Alfred Berg ABN AMRO Capital Investment + Handelsbanken)
	Person 2	Julander, Bengt (Pharmalink –201708 Board Chairman LEFT 8/17)

The Swedish specialty pharmaceutical company Pharmalink AB today announced the appointment of Thomas Eklund as new Chairman of the board.

Thomas Eklund joined the board on August 15, 2017.

“We are very happy to have Thomas on board as we prepare for taking our lead candidate drug Nefecon through a clinical Phase 3 study for patients with primary IgA nephropathy. Thomas’s broad knowledge and long experience from both the healthcare industry and the financial sector will be a welcome addition to the team”, said Bengt Julander, founder and outgoing Chairman of Pharmalink.

Thomas has extensive experience from the pharmaceutical and medtech industry, as well as the financial sector where he has held different leading positions, including CEO and Head of Europe at Investor Growth Capital AB. Other previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment AB and Vice President at Handelsbanken Markets. He is currently Chairman of the board of Moberg Pharma AB and Itrim AB, and board member of Boule Diagnostics AB, Biotage AB, Neoventa Medical AB, Memira AB, and Rodebjer Form AB.

Record changed: 2017-08-30

Advertisement

More documents for Calliditas Therapeutics (Group)

• [1] Calliditas Therapeutics AB. (8/25/20). "Press Release: Calliditas Appoints Group General Counsel"....
• [2] Calliditas Therapeutics AB. (8/13/20). "Press Release: Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA"....
• [3] Calliditas Therapeutics AB. (7/24/20). "Press Release: Calliditas Reorganizes Its Management Team"....
• [4] Calliditas Therapeutics AB. (7/2/20). "Press Release: Exercise of Over-allotment Option and End of the Stabilization Period"....
• [5] Calliditas Therapeutics AB. (6/5/20). "Press Release: Calliditas Therapeutics Prices Its Initial Public Offering on The Nasdaq Global Select Market in the United States"....
• [6] Calliditas Therapeutics AB. (5/14/20). "Press Release: Calliditas Publicly Files Registration Statement with SEC for a Proposed Initial Public Offering in the United States"....
• [7] Calliditas Therapeutics AB. (6/10/19). "Press Release: Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore"....
• [8] Calliditas Therapeutics AB. (1/8/19). "Press Release: Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America"....
• [9] Calliditas Therapeutics AB. (11/20/17). "Press Release: Surrogate Marker and Design of Calliditas Therapeutics’ IgA Nephropathy Phase 3 Study Agreed with the FDA". Stockholm....
• [10] Calliditas Therapeutics AB. (11/15/17). "Press Release: Pharmalink Is Renamed Calliditas Therapeutics"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.